Search

everythinglearnresearchcommunity

for

Search:↓

STS01 1% effectively promotes hair regrowth with minimal side effects.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.

Topical corticosteroids may be a safe and effective treatment for severe alopecia areata in children.

Diphenylcyclopropenone is more effective and has fewer side effects than dinitrochlorobenzene for treating alopecia areata.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

Tofacitinib is effective and safe for treating severe hair loss in Korean patients.

Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.

Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.

Tofacitinib is effective and safe for treating severe alopecia areata.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.

Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.

Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.

Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.

Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.

Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.

Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.

Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.

Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.

Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.

Getting insurance to cover the hair loss treatment tofacitinib is hard because it's not officially approved for that use.

HDAC inhibitors, like Vorinostat and Entinostat, can help regrow hair in alopecia areata.

Machine learning can predict how well patients with alopecia areata will respond to certain treatments.

Topical ruxolitinib cream may help treat frontal fibrosing alopecia.

Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.